EMILIO ALBA CONEJO – ENSAYO CLINICO COMERCIAL – MEDICA SCIENTIA INNOVATION RESEARCH, S.L.
Multicenter, open-label, phase II trial to evaluate the efficacy and safety of naI-IRI for progressing brain metastases in patients with HER2 negative breast cancer.
por prodriguez | Jul 3, 2024 | Ensayos Clínicos, Ensayos Clínicos - CIMO-01 | 0 Comentarios